NKTR

Nektar Therapeutics Stock Analysis

AI Rating

Good
  • Quality1/10
  • Growth↑ 5/10
  • Momentum↑ 9/10
Nektar Therapeutics sales and earnings growth
NKTR Growth
Neutral
  • Revenue Y/Y↓ -32.79%
  • EPS Y/Y↑ 37.79%
  • FCF Y/Y↑ 29.72%
Nektar Therapeutics gross and profit margin trends
NKTR Profitability
Low
  • Gross margin ↑ 87.30%
  • EPS margin↓ -192.90%
  • ROIC↓ -37.00%
Nektar Therapeutics net debt vs free cash flow
NKTR Risk
Good
  • Debt / Equity↓ 1.1
  • Debt / FCF↓ 0.4
  • Interest coverage↓ -3.6

Nektar Therapeutics stock volatility is higher than the overall market. We give it a Good risk rating.

More Biotechnology stocks ↗